Similarly, the GLP-1 receptor agonist, exenatide, and the DPP-4 inhibitor, sitagliptin, have been shown to reduce plasma apob-48 concentrations in humans [64,65], while in obesity, treatment with GLP-1 receptor agonists improves dyslipidaemia [66]. This evidence concerns the gene GLP1R and obesity disorder.